Last updated: 2026-09-28 18:55:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
BeyondSpring Inc. (BYSI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.93, with a market capitalization of $31.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.57 to $2.44. This page covers its latest market performance, valuation, price trends and company information.
$31.96M | |
$0.75 | |
$48.49 | |
$0.54 | |
$0.78 | |
1.43M | |
693.30K | |
-- | |
$2.44 | |
$0.57 | |
-- | |
-- |
BeyondSpring Inc. (BYSI) is currently trading at $0.93 as of 2026-09-28 18:53:00, up 19.40% ($0.15) from the previous close of $0.78
During today's regular trading session, BYSI has traded between $0.54 and $48.49, with a trading volume of 1.43M shares. The current price is near the lower end of today's range.
Over the past seven days, BeyondSpring Inc. (BYSI) moved from $0.71 to $0.93, representing a gain of 30.93% ($0.22).
The stock traded between $0.70 and $0.99 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 25.24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 19.3%
BYSI is currently trading at $0.93, placing it 19.3% of the way from its 52-week low of $0.57 to its 52-week high of $2.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 44 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BeyondSpring Inc. (BYSI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.